The most frequent adverse events classified as grade 3 or 4 events (CTCAE) included hypertension (14% of the patients), increased alanine transaminase activity (13%), increased aspartate aminotransferase activity (10%), hyponatremia (6%) and lymphopenia (6%). This evidence concerns the gene GPT and Hyponatremia.